Brain Benefits Boost Roche's Alecensa In ALK Lung Cancer Race
Executive Summary
Data from two studies confirm Alecensa's superiority over Pfizer's Xalkori and help Roche close the gap on Novartis' Zykadia.
You may also be interested in...
Roche’s Alecensa Goes Up Against Zykadia with First-Line NSCLC US FDA Approval
Expanded US approval for Alecensa in ALK-positive NSCLC will stand the product in good stead as it helps make up for upcoming biosimilar threat to Avastin, Rituxan and Herceptin.
Roche "Disappointed" By ASCO Focus, Progressing CEA-CD3 Bispecific
Roche CEO Severin Schwan says analysts at ASCO missed a key APHINITY message on Herceptin follow-on Perjeta, and that the Swiss group will swiftly progress its CEA-CD3 bispecific to pivotal studies based on data presented there.
Novartis’ Zykadia ASCEND-4 Study Close But No Cigar In NSCLC
The presentation of the full data from Novartis’ ASCEND-4 study of Zykadia show decent efficacy in first-line NSCLC but are unlikely to be enough to overcome doctors’ caution over its tolerability profile, especially with rival Alecensa snapping at its heels.